Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.

Authors: Luis G. Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, Katarzyna Magdalena Stencel, Margarita Majem, Grzegorz Czyżewicz, Reyes Bernabe Caro, Ki Hyeong Lee, Melissa Lynne Johnson, Nuri Karadurmus, Christian Grohe, Vaikunth Cuchelkar, Vilma Graupner, Monika Dulloo Kaul, Ya-Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, Martin Reck

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.8006

Source: Full article


Abstract

8006